BioTime (Israel) Management Performance Evaluation

BTX -- Israel Stock  

ILS 409.00  7.10  0.02%

Analysis of BioTime manpower and management performance can provide insight into BioTime stock performance. Also an employee sentiment is becoming a valuable factor that investors can use to determine the amount of risk that may be associated with BioTime future performance. Check also Trending Equities.

BioTime Management Effectiveness

The company has return on total asset (ROA) of (12.67) % which means that it has lost $12.67 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (39.03) % meaning that it generated substantial loss on money invested by shareholders.

BioTime Workforce Comparison

BioTime is rated below average in number of employees category among related companies. The total workforce of Biotechnology industry is currently estimated at about 1,251. BioTime holds roughly 92.0 in number of employees claiming about 7% of stocks in Biotechnology industry.

BioTime Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of thirty-nine. BioTime Price Series Summation is a cross summation of BioTime price series and its benchmark/peer. View also all equity analysis or get more info about price series summation math operators indicator.

BioTime Stakeholders

Michael West Co-CEO, Director
Brian Culley President CEO, Director
Pedro Lichtinger President CEO of Asterias Biotherapeutics
Aditya Mohanty Co-President Co-CEO, Director
Alfred Kingsley Chairman of the Board
Judith Segall Vice President - Administration, Corporate Secretary, Director
Russell Skibsted CFO
Michael Mulroy Director
David Schlachet Independent Director
Deborah Andrews Independent Director
David Nakasone Director - Investor Relations
Neal Bradsher Independent Director
Angus Russell Director
Cavan Redmond Independent Director
Stephen Farrell Independent Director
Stephana Patton General Counsel
Matt Haines IR Contact Officer

BioTime Leadership

BioTime Top Executives

  Michael West  CEO
Co-CEO, Director
  Brian Culley  CEO
President CEO, Director

BioTime Tenure Analysis

BioTime Employment Tenure

BioTime employes about 92 people. The company is managed by 17 executives with total tenure of roughly 73 years, averanging almost 4.0 years of service per executive having 5.0 employee per reported executive.

BioTime Manpower Efficiency

Return on BioTime Manpower

Revenue Per Employee56.8 K
Revenue Per Executive307.6 K
Net Loss Per Employee793.2 K
Net Loss Per Executive4.3 M
Check also Trending Equities. Please also try World Markets Correlation module to find global opportunities by holding instruments from different markets.
Search macroaxis.com